Results 1 to 10 of about 16,008 (114)
Case Report: Semaglutide-associated depression: a report of two cases
Frontiers in Psychiatry, 2023 Semaglutide, as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was approved for glucose control in type 2 diabetes mellitus in 2017 and approved for weight loss in 2021 by the U.S. Food and Drug Administration (FDA). No psychiatric adverse effect
Jinya Cao, Wenqi Geng
exaly +3 more sources
Electroacupuncture enables semaglutide dose sparing in type 2 diabetes by boosting drug concentration and suppressing β-cell apoptosis [PDF]
Frontiers in EndocrinologyPurposeSemaglutide is effective for type 2 diabetes mellitus (T2DM) but limited by dose-dependent gastrointestinal adverse effects. As electroacupuncture (EA) possesses glucose-lowering effects, this study investigates the therapeutic potential and ...
Xinyi Yang +15 more
doaj +2 more sources
Frontiers in Endocrinology, 2021 The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation.
Mark M Smits +2 more
exaly +3 more sources
Redox BiologyAims: Doxorubicin is a powerful chemotherapeutic agent for cancer, whose use is limited due to its potential cardiotoxicity. Semaglutide (SEMA), a novel analog of glucagon-like peptide-1 (GLP-1), has received widespread attention for the treatment of ...
Chunyu Zeng
exaly +3 more sources
Oral vs. Subcutaneous Semaglutide for Obesity Treatment: A Systematic Review of Efficacy, Safety, and Patient-Oriented Outcomes [PDF]
PharmaceuticalsBackground/Objectives: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), is approved for weight management as both a weekly subcutaneous (s.c.) injection (2.4 mg) and a daily oral tablet (50 mg). Although head-to-head trials are lacking,
Sandro La Vignera, Rosita A. Condorelli
doaj +2 more sources
Contemporary Clinical Trials Communications, 2022 Aim: Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) indicated for glycaemic management in adults with type 2 diabetes (T2D).
Yousef Alhindi, Amanda Avery
doaj +1 more source
Frontiers in Pharmacology, 2021 Introduction: Semaglutide is the first and only oral version of a glucagon-like peptide-1 analogue approved by the FDA for the treatment of type 2 diabetes (T2D). This research was designed to explore the appropriate price of once-weekly (OW) semaglutide
Shanshan Hu +6 more
doaj +1 more source
EBioMedicine, 2023 Summary: Background: Glucagon-like peptide1 receptor (GLP-1R) agonists have been found to reduce alcohol drinking in rodents and overweight patients with alcohol use disorder (AUD).
Cajsa Aranäs +9 more
doaj +1 more source
Population pharmacokinetic of paracetamol and atorvastatin with co‐administration of semaglutide
Pharmacology Research & Perspectives, 2022 Semaglutide is a glucagon‐like‐peptide‐1 (GLP‐1) analogue marketed for once‐weekly subcutaneous administration for type 2 diabetes mellitus. Like other long‐acting GLP‐1 analogues, semaglutide reduces gastric emptying and, potentially, alters the rate of
Emilie K. Langeskov, Kim Kristensen
doaj +1 more source
Clinical Pharmacokinetics of Semaglutide: A Systematic Review
Drug Design, Development and TherapyXi-Ding Yang,1,2 Yong-Yu Yang1,3 1Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, Hunan, People’s Republic of China; 2Phase I Clinical Trial Center, The Second Xiangya Hospital of Central South University ...
XiDing Yang, Yong-Yu Yang
exaly +2 more sources